GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Global Recommendation, Swissmedic Approval, and SL Limitation
WHO Guidelines on GLP-1 for Obesity
- Obesity in Children and Adolescents
Gene-Environment Interactions: Polygenic or Monogenic Determinants?
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- H. pylori infection: current study data
Fewer gastric carcinomas and peptic ulcers after eradication
- From symptom to diagnosis
Pneumology – tracheal and bronchial calcifications
- Tinea capitis: Current Guidelines and Recommendations